In Brief: Menlo Care Landmark aquavene midline catheters
This article was originally published in The Gray Sheet
Menlo Care Landmark aquavene midline catheters: Panel of experts meeting the week of Jan. 28 to review adverse reactions to the devices "concluded that there is no clear pattern regarding their etiology" and that the Aquavene biomaterial is non-allergic and non-toxic, according to a release from Menlo Care's parent company Johnson & Johnson. FDA recently met with Menlo Care out of concern over adverse event reports with the catheters, and will evaluate the devices along with other manufacturers' catheters in an upcoming prospective clinical trial ("The Gray Sheet" Jan. 22, I&W-13). The Feb. 9 "Morbidity and Mortality Weekly Report" from the Centers for Disease Control and Prevention notes that adverse reactions with the Landmark catheter have often occurred within 20-30 minutes of catheter insertion, "suggesting that the cause of the reactions may be extrinsic to the catheter" with the causative agent "potentially dislodged during flushing"...
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.